Table 4.
Correlations between clinicopathological parameters and survival in locally advanced rectal cancer
| Parameters | Cases | 5-year DFS, % | P-value | 5-year OS, % | P-value |
|---|---|---|---|---|---|
| Age, years | |||||
| <62 | 50 | 66.3 | 0.801 | 80.1 | 0.391 |
| ≥62 | 69 | 62.3 | 68.5 | ||
| Sex | |||||
| Male | 74 | 65.6 | 0.629 | 74.1 | 0.924 |
| Female | 45 | 61.3 | 71.1 | ||
| Distance from anal verge, cm | |||||
| <6 | 42 | 61.2 | 0.379 | 72.5 | 0.731 |
| ≥6 | 77 | 65.3 | 73.0 | ||
| Histology | |||||
| Differentiated | 66 | 66.0 | 0.893 | 77.9 | 0.338 |
| Undifferentiated | 53 | 61.8 | 67.5 | ||
| cT stage | |||||
| 3 | 68 | 70.3 | 0.037 | 78.7 | 0.041 |
| 4 | 51 | 55.3 | 63.1 | ||
| cN stage | |||||
| Negative | 39 | 77.1 | 0.021 | 84.2 | 0.027 |
| Positive | 80 | 57.2 | 65.9 | ||
| Chemotherapy regimens | |||||
| 5-FU/capecitabine | 68 | 60.7 | 0.213 | 72.6 | 0.346 |
| Capecitabine/5-FU and oxaliplatin | 51 | 68.4 | 75.0 | ||
| HER-2 | |||||
| Positive | 22 | 50.8 | 0.015 | 55.6 | 0.026 |
| Negative | 97 | 67.2 | 76.8 | ||
5-FU, 5-fluorouracil; DFS, disease-free survival; HER-2, human epidermal growth factor receptor-2; OS, overall survival.